替格瑞洛、氯吡格雷治疗冠心病心肌缺血的疗效差异研究

Effect of Tigrilol and Clopidogrel on Myocardial Ischemia in Coronary Heart Disease

目的:分析对冠心病心肌缺血患者实施替格瑞洛、氯吡格雷治疗的临床疗效。方法:从2018年12月~2020年2月择取100例冠心病心肌缺血患者,将其随机分为对照组和研究组各50例,对照组患者实施氯吡格雷治疗,研究组患者实施替格瑞洛治疗,对照分析两组临床效果。结果:从临床疗效来看,研究组总有效率高于对照组(P<0.05);从血压及心率来看,治疗后研究组舒张压、收缩压、心率均优于对照组(P<0.05);从血管内皮功能来看,治疗后研究组血浆内皮素、血栓素B2均优于对照组(P<0.05);从不良反应发生情况来看,研究组心力衰竭、消化道出血、心绞痛、心肌梗死等不良反应总发生率低于对照组(P<0.05)。结论:对于冠心病心肌缺血患者来说,相比于氯吡格雷,替格瑞洛治疗效果更佳,不仅可以调节心率和血压,还可以改善血管内皮功能,避免不良反应发生,临床价值显著。

Objective:To analyze the clinical effect of tigrilol and clopidogrel in patients with myocardial ischemia of coronary heart disease.Methods:From December 2018 to February 2020,100 patients with myocardial ischemia of coronary heart disease were selected and randomly divided into two groups.The control group(50 patients)were treated with clopidogrel,and the study group(50 patients)were treated with tigrilol,then the clinical effect of the two groups was analyzed.Results:The total effective rate of the study group was higher than that of the control group(P<0.05).According to blood pressure and heart rate,the diastolic pressure,systolic blood pressure and the heart rate after treatment in the study group were better than those in the control group(P<0.05).The plasma endothelin and thromboxane B2 in the study group were better than those in the control group(P<0.05).The total incidence of adverse reactions such as heart failure,gastrointestinal bleeding,angina pectoris,myocardial infarction in the study group was lower than that in the control group(P<0.05).Conclusion:Compared with clopidogrel,tigrilol is more effective in the treatment of patients with coronary heart disease myocardial ischemia,which can not only regulate heart rate and blood pressure,but also improve vascular endothelial function and avoid adverse reactions,with significant clinical value.